As shown in Figure 3 and Supplementary Figure 2C, FAM83D siRNA-treated AGS and SGC-7901 cells led to a significant increase in the proportion of tumor cells at the G2-M phase (AGS: 23.26% ± 2.65% vs. 17.42% ± 2.36%, P < 0.05; SGC-7901: 27.67% ± 3.96% vs. 19.68% ± 1.86%, P < 0.05). Here, SACK1D is linked to neoplasm.